In comparison with general population cancer registries, there appeared to be no higher risk for all-sites primary cancers in GH-treated patients in GeNeSIS, the same finding as in analyses of patients without risk factors for malignancy from both the KIGS and NCGS databases (2, 30). This evidence concerns the gene GH1 and cancer.